Drugs / Murine CD19 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04532281 | Nov 2020 → Nov 2023 overdue | acute lymphoblastic leukemia | Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Murine CD19 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04532281 ↗ |
| Modality | Cell therapy | “Murine CD19 CAR-T cells” NCT04532281 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT04532281 ↗ |
| Target | CD19 | “Murine CD19 CAR-T cells” NCT04532281 ↗ |